Search
On November 24, 2025, Junshi Biosciences announced that its independently developed Toripalimab Injection (subcutaneous injection, code name JS001sc) had reached the primary endpoint in a Phase III clinical study comparing it with Toripalimab Injection combined with chemotherapy as a first-line treatment for recurrent or metastatic non-squamous non-small cell lung cancer. The study planned to enroll 356 patients and aimed to compare the differences in drug exposure, efficacy, and safety between JS001sc and Toripalimab Injection combined with chemotherapy. The results showed that the drug exposure of JS001sc was non-inferior to that of Toripalimab Injection, and both exhibited similar efficacy and safety profiles. Junshi Biosciences plans to submit a marketing authorization application for JS001sc in the near future.
-
C114 Communication Network -
Communication Home
